文献速递妇科肿瘤

EMPOWER CERVICAL-1:西米普利单抗对比化疗对复发宫颈癌女性患者报告的生活质量、功能和症状的影响

EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
PubMed 文献 · Eur J Cancer · 2022-07-31

在复发宫颈癌铂类治疗后进展的患者中,这项III期随机对照研究比较西米普利单抗与研究者选择化疗的患者报告结局;西米普利单抗在总体健康状况/生活质量及躯体功能方面显示出统计学显著且有利于西米普利单抗的组间差异,并在角色功能、食欲减退和疼痛方面有临床意义的差异。

要点

  • 西米普利单抗组总体健康状况/生活质量组间差异为8.49(95%CI 3.77-13.21;P=0.0003)。
  • 西米普利单抗组躯体功能组间差异为8.35(95%CI 4.08-12.62;P<0.0001)。
  • 两种组织学人群至第2周期即显示有利于西米普利单抗的治疗差异。

核心结论

  • 在复发宫颈癌患者中,西米普利单抗相比化疗在总体健康状况/生活质量和躯体功能方面带来有利差异,躯体功能获益至第2周期出现,角色功能、食欲减退和疼痛方面有临床意义的差异且有利于西米普利单抗。

研究设计与样本

  • III期随机开放标签阳性对照研究(EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9;R2810-ONC-1676;NCT03257267),共608例患者按1:1随机分配至西米普利单抗组或研究者选择化疗组,每组304例。
  • 西米普利单抗350 mg静脉给药每3周一次;研究者选择化疗以6周为周期。
  • 患者在周期1-16期间完成欧洲癌症研究与治疗组织生活质量问卷核心30(EORTC QLQ-C30)。

主要发现

  • 77.8%患者为鳞状细胞癌,22.2%患者为腺癌;问卷完成率全程约90%。
  • 鳞状细胞癌人群中,总体健康状况/生活质量组间差异为8.49(95%CI 3.77-13.21;P=0.0003),躯体功能组间差异为8.35(95%CI 4.08-12.62;P<0.0001),均统计学显著有利于西米普利单抗。
  • 两种组织学人群至第2周期即显示有利于西米普利单抗的治疗差异。
  • 大多数功能与症状量表较基线的总体变化有利于西米普利单抗,两种人群中角色功能、食欲减退和疼痛的治疗差异具有临床意义。
  • 敏感性分析、应答者分析和至确定性恶化时间在两种人群中均有利于西米普利单抗。

关键数值与推荐

  • 总体健康状况/生活质量为次要终点,组间差异8.49(95%CI 3.77-13.21;P=0.0003),有利于西米普利单抗。
  • 躯体功能为次要终点,组间差异8.35(95%CI 4.08-12.62;P<0.0001),有利于西米普利单抗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In a phase III, randomised, active-controlled study (EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9; R2810-ONC-1676; NCT03257267) and cemiplimab significantly improved survival versus investigator's choice of chemotherapy among patients with recurrent cervical cancer who had progressed on platinum-based therapy. Here we report patient-reported outcomes in this pivotal study. METHODS: Patients were randomised 1:1 to open-label cemiplimab (350 mg intravenously every 3 weeks) or investigator's choice of chemotherapy in 6-week cycles. Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 during cycles 1-16. Least-squares mean changes from baseline in global health status (GHS)/quality of life (QoL) and physical functioning (PF) were secondary end-points in the statistical hierarchy. RESULTS: Of 608 patients (304/arm), 77.8% patients had squamous cell carcinoma and 22.2% patients had adenocarcinoma. Questionnaire completion rates were ∼90% throughout. In the squamous cell carcinoma population, overall between-group differences statistically significantly favoured cemiplimab in GHS/QoL (8.49; 95% confidence interval [CI]: 3.77-13.21; P = 0.0003) and PF (8.35; 95% CI: 4.08-12.62; P < 0.0001). Treatment differences favoured cemiplimab in both histologic populations by cycle 2. Overall changes from baseline in most functioning and symptom scales favoured cemiplimab, with clinically meaningful treatment differences in role functioning, appetite loss and pain in both populations. The sensitivity analyses, responder analyses and time to definitive deterioration favoured cemiplimab in both populations. CONCLUSIONS: Cemiplimab conferred favourable differences in GHS/QoL and PF compared with chemotherapy among patients with recurrent cervical cancer, with benefits in PF by cycle 2, and clinically meaningful differences favouring cemiplimab in role functioning, appetite loss, and pain.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Oaknin A, Monk BJ, Vergote I, et al. EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer. Eur J Cancer. 2022. PMID: 35922251. doi:10.1016/j.ejca.2022.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。